Interferons in relapsing remitting multiple sclerosis.

Interferons in relapsing remitting multiple sclerosis.

Detalhes bibliográficos
Autor principal:	Goodin, D
Formato:	Journal article
Idioma:	English
Publicado em:	2003

Registros relacionados

Interferons in relapsing remitting multiple sclerosis - Authors' reply
por: Filippini, G, et al.
Publicado em: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
por: Filippini, G, et al.
Publicado em: (2003)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
por: Filippini, G, et al.
Publicado em: (2003)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Làzaro Aurelio Vàzquez Gòmez, et al.
Publicado em: (2022-10-01)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
por: Wylezinska, M, et al.
Publicado em: (2003)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
por: Cifelli, A, et al.
Publicado em: (2003)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
por: O.V. Somilo, et al.
Publicado em: (2024-10-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
por: Petkau, A, et al.
Publicado em: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
por: Petkau, A, et al.
Publicado em: (2004)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
por: Rahil Sadat Shahtaheri, et al.
Publicado em: (2018-06-01)

Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report
por: Taras O. Simaniv, et al.
Publicado em: (2024-12-01)

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
por: Fernando Rodríguez-Jorge, et al.
Publicado em: (2024-11-01)

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
por: Lesage, E, et al.
Publicado em: (2010)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: E. Lesage, et al.
Publicado em: (2010-01-01)

Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines
por: Paty, D, et al.
Publicado em: (1999)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
por: Fernando Rodríguez-Jorge, et al.
Publicado em: (2024-12-01)

Prooxidant-antioxidant balance in relapsing-remitting multiple sclerosis patients
por: Samaneh Sabouri, et al.
Publicado em: (2023-07-01)

The condition of the cardiovascular system in patients with relapsing-remitting multiple sclerosis
por: O. A. Traktirskaya, et al.
Publicado em: (2019-03-01)

Efficacy and Safety of PEGylated Interferons for Relapsing-Remitting Multiple Sclerosis in Adult Patients: Results of Matching-Adjusted Indirect Comparison
por: Taras O. Simaniv, et al.
Publicado em: (2024-04-01)

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
por: Ebers, G, et al.
Publicado em: (1998)

Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
por: Rozanna Meijboom, et al.
Publicado em: (2023-01-01)

Are Sirtuins 1 and 2 Relevant Players in Relapsing–Remitting Multiple Sclerosis?
por: Justyna Chojdak-Łukasiewicz, et al.
Publicado em: (2024-09-01)

Ocrelizumab alters the circulating metabolome in people with relapsing–remitting multiple sclerosis
por: Fatemeh Siavoshi, et al.
Publicado em: (2024-09-01)

A review of treatment of relapsing-remitting type of multiple sclerosis (RRMS)
por: Arkadiusz Bydliński, et al.
Publicado em: (2024-05-01)

Meta‐analysis of the use of Ofatumumab in the treatment of relapsing‐remitting multiple sclerosis
por: Peter Olujimi Odutola, et al.
Publicado em: (2023-09-01)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
por: Fatemeh Yavari, et al.
Publicado em: (2021-03-01)

Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
por: Reder, A, et al.
Publicado em: (2010)

Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis
por: F. A. Khabirov, et al.
Publicado em: (2024-08-01)

Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple-sclerosis
por: Silvia Boullosa-Lale, et al.
Publicado em: (2021-03-01)

Clinical features of cognitive dysfunction in patients with relapsing-remitting type of multiple sclerosis
por: O.S. Teslenko, et al.
Publicado em: (2024-03-01)

In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
por: Fianne L. P. Sips, et al.
Publicado em: (2022-11-01)

Predictive factors and treatment challenges in malignant progression of relapsing-remitting multiple sclerosis
por: Masoud Ghiasian, et al.
Publicado em: (2024-02-01)

Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability
por: S. Migliore, et al.
Publicado em: (2017-01-01)

Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis
por: Ahmad, H, et al.
Publicado em: (2018)

De novo relapsing-remitting multiple sclerosis following autologous stem cell transplantation.
por: Armstrong, R, et al.
Publicado em: (2010)

Comparative Effects of Vitamin D Supplementation on Oxidative Stress in Relapsing–Remitting Multiple Sclerosis
por: Martyna Lis, et al.
Publicado em: (2024-12-01)

Decrease of Mutual Information in Brain Electrical Activity of Patients with Relapsing-Remitting Multiple Sclerosis
por: Bruno Lenne, et al.
Publicado em: (2013-01-01)

3 Managing disease activity during treatment with natalizumab in relapsing-remitting multiple sclerosis
por: Nevin John, et al.
Publicado em: (2024-08-01)

Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?
por: Martyna Lis, et al.
Publicado em: (2024-07-01)

A pilot study of monocytes in relapsing remitting multiple sclerosis: Correlation with disease activity
por: Sara I Taha, et al.
Publicado em: (2024-07-01)